Sep. 4 at 6:33 PM
$RCUS They keep saying they love to work with
$AZN.
Not for the first time. They don't even mention Gilead.
They said that when they present next month, the data will show that Casdatifan is much better than the SOC from Merck.
I'm not sure if you're familiar with
$SMMT.
When
$SMMT reported better data than Merck's Kytrudra, the stock jumped from
$2 to
$11 in one day. Eventhough the data was from a Chinese trial that no one can trust.
He also said that until now they compared early data to later data from Merck. That data gets better over time. He said the data will show black on white the superiority of Casdatifan.
I'm shocked how much they hint.
